Results 51 to 60 of about 811,174 (190)

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

open access: yesJournal of Hematology & Oncology, 2022
Bruton’s tyrosine kinase (BTK) is an essential component of multiple signaling pathways that regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising therapeutic target for various B cell malignancies and ...
Aqu Alu   +4 more
doaj   +1 more source

The synergistic impact of granulocytic myeloid‐derived suppressor cells and innate lymphoid cells in systemic sclerosis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by immune dysregulation and fibrosis, with myeloid‐derived suppressor cells (MDSCs) emerging as important regulators of immune responses. However, the role of MDSCs in SSc‐associated fibrosis and their interactions with other immune cell populations remain poorly ...
Stefanie Weber   +15 more
wiley   +1 more source

Emerging therapy targeting tyrosine-protein kinase BTK: potential for ibrutinib and other BTK inhibitors

open access: yes, 2013
Tyrosine-protein kinase BTK (Bruton tyrosine kinase) plays a critical role in the B cell receptor signaling pathway, and as such, mediates many immune responses.
S.A. Rushworth   +5 more
core   +1 more source

Treatment‐Driven Peripheral Blood Transcriptomic Remodeling and Baseline Predictors of ESSDAI and STAR Response to B Cell Therapy in Sjögren's Disease

open access: yesArthritis &Rheumatology, EarlyView.
Graphical Abstract Objective This study aimed to characterize whole blood transcriptomic profiles in adults with active Sjögren's disease (SjD) treated with anti‐CD20 or B lymphocyte stimulator/BAFF inhibition, identify markers of clinical response, and define inflammatory pathways linked to nonresponse. Methods Whole blood RNA sequencing was performed
Aimen Ibrahim   +9 more
wiley   +1 more source

A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase

open access: yesRoyal Society Open Science, 2021
Bruton's tyrosine kinase (BTK) plays a vital role in mature B-cell proliferation, development and function. Its inhibitors have gradually been applied for the treatment of many B-cell malignancies. However, because of treatment-associated drug resistance
Simei Qiu, Yunfeng Liu, Quhuan Li
doaj   +1 more source

Discovery of Pteridine-7(8H)one Derivatives as Potent and Selective Inhibitors of Brutons Tyrosine Kinase (BTK)

open access: yes, 2022
Bruton’s tyrosine kinase (BTK) is an attractive therapeutic target in the treatment of cancer, inflammation, and autoimmune diseases. Covalent and noncovalent BTK inhibitors have been developed, among which covalent BTK inhibitors have shown great ...
Zhenjiang Zhao   +33 more
core   +1 more source

Discovery of 1‑Amino‑1H‑imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors

open access: yes, 2021
Bruton’s tyrosine kinase (BTK) inhibitors suppressing the aberrant activation of BTK have led to a paradigm shift in the therapy of B-cell malignancies. However, there is an urgent need to discover more selective covalent BTK inhibitors owing to the off ...
Liang Zhu (172992)   +14 more
core   +3 more sources

Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi‐scenario applications, and translational prospects

open access: yesSmart Molecules, EarlyView.
AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin   +10 more
wiley   +1 more source

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa   +25 more
wiley   +1 more source

Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)

open access: yesAdvances in Hematology, 2022
Of the variety of immunoglobulin related amyloidosis (AL), immunoglobulin M (IgM) related AL represents only 6 to 10% of affected patients, and the majority of these cases are associated with underlying non-Hodgkin’s Lymphoma including Waldenström’s ...
Maroun Bou Zerdan   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy